Kymera IPO Presentation Deck

IRAKIMID Superior to IRAK4 Inhibition and IMID Single Agents MYD88-mutated ABC- DLBCL cell lines OCI-Ly10 and SUDHL2 evaluated in a 4-day viability assay - Activity of IRAKIMID compared to an IMID compound alone and IRAK4 kinase inhibitor alone assessed + IRAKIMID degrader (ICso 31 nM) significantly more selective and efficient than IRAK4 SM kinase inhibitor or a third generation clinically active IMID CC-122 in cell viability KYMERA % Viability (4D CTG) 100- 75- 50 OCI-Ly10 Log [Compound] (μM) % Viability (4D CTG) 100 IRAK4 KI CC122 75 50 25 IRAKIMID Degrader SUDHL2 Log [Compound] (μM)

View entire presentation